Revenue: As of FY2025, the actual value is USD 456.02 K.EPS: As of FY2025, the actual value is USD -2.17.<h4>Segment Revenue</h4><ul><li>Revenue for Mangoceuticals, Inc. was $456,021 in 2025, a decrease from $615,873 in 2024, primarily due to issues with the transition and migration to a new telehealth platform .</li></ul><h4>Operational Metrics</h4><ul><li>Cost of Revenues:<ul><li>Cost of revenues was $54,422 in 2025, down from $93,296 in 2024, attributed to fluctuations in service usage and delivery costs .</li><li>Cost of revenues - related party (amounts paid to Epiq Scripts) increased to $151,213 in 2025 from $142,613 in 2024, due to increased cost of goods from the related party pharmacy .</li></ul></li><li>Gross Profit:<ul><li>Gross profit was $250,386 in 2025, compared to $379,964 in 2024 .</li></ul></li><li>Operating Expenses:<ul><li>General and Administrative Expenses increased to $3,756,373 in 2025 from $3,000,571 in 2024, mainly due to consulting and accounting expenses, offset by reductions in software, legal, and travel .</li><li>Salary and Benefits increased to $1,348,051 in 2025 from $1,063,781 in 2024, due to the engagement of new management and staff employees .</li><li>Advertising and Marketing decreased to $822,860 in 2025 from $1,478,663 in 2024, related to a reduction in efforts while focusing on the website re-launch .</li><li>Investor Relations increased significantly to $1,561,206 in 2025 from $453,749 in 2024, due to expanded efforts to raise public awareness .</li><li>Stock-Based Compensation increased to $10,794,245 in 2025 from $2,355,193 in 2024, reflecting greater use of equity-based incentives and higher stock prices .</li><li>Total Operating Expenses totaled $18,282,735 in 2025, compared to $8,351,957 in 2024 .</li></ul></li><li>Loss from Operations:<ul><li>Loss from operations was -$18,032,349 in 2025, compared to -$7,971,993 in 2024 .</li></ul></li><li>Other (Income) Expense:<ul><li>Interest Expense increased to $103,513 in 2025 from $13,700 in 2024, due to accrued interest on notes payable .</li><li>Amortization of Intangible Assets was $1,122,639 in 2025, up from $721,533 in 2024 .</li><li>Impairment of License Agreement was recognized at $1,239,942 in 2025 .</li><li>Loss from Settlement totaled $125,624 in 2025 due to legal settlements .</li><li>Loss from Debt Extinguishment - Related Parties was $19,388 in 2025 .</li></ul></li><li>Net Loss:<ul><li>Net loss for 2025 was -$20,643,455, an increase of $11,823,899 from -$8,707,226 in 2024, primarily due to decreased revenue and increased general and administrative expenses, stock-based compensation, and investor relations expenses .</li></ul></li></ul><h4>Financial Position Metrics</h4><ul><li>Cash and Cash Equivalents: Increased to $1,486,338 in 2025 from $58,653 in 2024, mainly due to financing activities .</li><li>Working Capital: Positive working capital of $0.6 million in 2025, compared to a working capital deficit of -$1.3 million in 2024 .</li><li>Total Assets: Total assets were $16,089,573 in 2025, compared to $15,370,511 in 2024 .</li><li>Total Liabilities: Total liabilities were $890,568 in 2025, compared to $1,425,463 in 2024 .</li><li>Accumulated Deficit: Accumulated deficit was -$40,647,480 in 2025, compared to -$20,004,486 in 2024 .</li><li>Intangible Assets (Acquired Patents and License, Net): Intangible assets were $14,232,484 in 2025, compared to $15,232,617 in 2024, after accounting for an impairment of $1,239,942 on the license agreement .</li></ul><h4>Cash Flow</h4><ul><li>Operating Activities: Net cash used in operating activities was -$5,850,255 in 2025, primarily due to the net loss, offset by non-cash items like stock-based compensation, amortization, and impairment . In 2024, net cash used was -$4,863,776 .</li><li>Investing Activities: There was no net cash used in investing activities in 2025, while in 2024, net cash provided by investing activities was $65,000 from the sale of assets .</li><li>Financing Activities: Net cash provided by financing activities was $7,270,855 in 2025, mainly from proceeds from common stock sales, warrant exercises, subscription collection, Series B Convertible preferred stock sales, borrowings from the CEO, and a third-party note payable . In 2024, net cash provided was $4,128,268 .</li></ul><h4>Outlook / Guidance</h4>Mangoceuticals, Inc. anticipates needing additional funding for the next 12 months to maintain current operations and cover public company costs, potentially through debt or equity offerings that may dilute existing shareholders . The company plans an aggressive growth strategy by expanding operations through marketing, technology enhancements, new product development, and strategic acquisitions, funding permitting . The Board of Directors is also evaluating potential strategic alternatives, including mergers, acquisitions, and divestitures, to maximize shareholder value, though without a definitive timeline or assurance of a specific outcome .

Mangoceuticals | 10-K: FY2025 Revenue: USD 456.02 K